Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.
2.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
3.

Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.

Shearer AT, Bagust A, Ampudia-Blasco FJ, Martínez-Lage Alvarez B, Pérez Escolano I, París G.

Pharmacoeconomics. 2006;24 Suppl 1:49-59. Review.

PMID:
16800162
4.

The economics of diabetes prevention.

Herman WH.

Med Clin North Am. 2011 Mar;95(2):373-84, viii. doi: 10.1016/j.mcna.2010.11.010. Review.

5.
6.

The potential of metformin for diabetes prevention.

Slama G.

Diabetes Metab. 2003 Sep;29(4 Pt 2):6S104-11. Review.

PMID:
14502107
7.

An update on the Diabetes Prevention Program.

Ratner RE; Diabetes Prevention Program Research..

Endocr Pract. 2006 Jan-Feb;12 Suppl 1:20-4. Review.

8.

Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective.

Neeser K, Lübben G, Siebert U, Schramm W.

Pharmacoeconomics. 2004;22(5):321-41. Review.

PMID:
15061682
9.

Time to give nutrition interventions a higher profile: cost-effectiveness of 10 nutrition interventions.

Dalziel K, Segal L.

Health Promot Int. 2007 Dec;22(4):271-83. Epub 2007 Oct 4. Review.

PMID:
17916604
10.

Economic Evaluation of Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among Persons at Increased Risk: A Systematic Review for the Community Preventive Services Task Force.

Li R, Qu S, Zhang P, Chattopadhyay S, Gregg EW, Albright A, Hopkins D, Pronk NP.

Ann Intern Med. 2015 Sep 15;163(6):452-60. doi: 10.7326/M15-0469. Review.

11.

Cost effectiveness of liraglutide in type II diabetes: a systematic review.

Zueger PM, Schultz NM, Lee TA.

Pharmacoeconomics. 2014 Nov;32(11):1079-91. doi: 10.1007/s40273-014-0192-4. Review.

PMID:
25052903
12.

Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program.

Goldberg RB, Mather K.

Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2077-90. doi: 10.1161/ATVBAHA.111.241893. Review.

13.

Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review.

Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X.

Diabetes Care. 2010 Aug;33(8):1872-94. doi: 10.2337/dc10-0843. Review.

14.

The prevention of type 2 diabetes.

Crandall JP, Knowler WC, Kahn SE, Marrero D, Florez JC, Bray GA, Haffner SM, Hoskin M, Nathan DM; Diabetes Prevention Program Research Group..

Nat Clin Pract Endocrinol Metab. 2008 Jul;4(7):382-93. doi: 10.1038/ncpendmet0843. Epub 2008 May 20. Review.

15.

Implications of the diabetes prevention program and Look AHEAD clinical trials for lifestyle interventions.

Delahanty LM, Nathan DM.

J Am Diet Assoc. 2008 Apr;108(4 Suppl 1):S66-72. doi: 10.1016/j.jada.2008.01.026. Review.

16.

Prevention of type 2 diabetes: risk status, clinic, and community.

Narayan KM, Williamson DF.

J Gen Intern Med. 2010 Feb;25(2):154-7. doi: 10.1007/s11606-009-1148-9. Epub 2009 Nov 5. Review.

17.

The reality of type 2 diabetes prevention.

Kahn R, Davidson MB.

Diabetes Care. 2014 Apr;37(4):943-9. doi: 10.2337/dc13-1954. Review.

18.

Design of a family-based lifestyle intervention for youth with type 2 diabetes: the TODAY study.

TODAY Study Group..

Int J Obes (Lond). 2010 Feb;34(2):217-26. doi: 10.1038/ijo.2009.195. Epub 2009 Oct 13. Review.

19.

Therapeutic Challenges in Diabetes Prevention: We Have Not Found the "Exercise Pill".

Srinivasan S, Florez JC.

Clin Pharmacol Ther. 2015 Aug;98(2):162-9. doi: 10.1002/cpt.146. Epub 2015 Jun 25. Review.

20.

Workplace Interventions to Prevent Type 2 Diabetes Mellitus: a Narrative Review.

Hafez D, Fedewa A, Moran M, O'Brien M, Ackermann R, Kullgren JT.

Curr Diab Rep. 2017 Feb;17(2):9. doi: 10.1007/s11892-017-0840-0. Review.

PMID:
28150162

Supplemental Content

Support Center